Innovative therapeutics

RSS Feed

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News

Email Alerts

Jun 29, 2020

BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President,...

Jun 23, 2020

BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate...

Jun 17, 2020

BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an...

Events & Presentations

BofA Securities 2020 Napa Biopharma Conference

Wednesday, June 24, 2020

8:30am - 9:30am PDT

4-year Valoctocogene Roxaparvovec Program Update Webinar

Wednesday, June 17, 2020

2:00pm - 3:00pm PDT